Synthetic Strigolactone Analogues Reveal Anti-Cancer Activities on Hepatocellular Carcinoma Cells
AuthorsHasan, Mohammed Nihal
Razvi, Syed Shoeb
Moselhy, Said Salama
Kumosani, Taha Abduallah
Zamzami, Mazin A.
Halwani, Majed A.
Abualnaja, Khalid Omer
Al-Malki, Abdulrahman Labeed
KAUST DepartmentBiological and Environmental Sciences and Engineering (BESE) Division
Plant Science Program
Desert Agriculture Initiative
Computational Bioscience Research Center (CBRC)
Permanent link to this recordhttp://hdl.handle.net/10754/627127
MetadataShow full item record
AbstractHepatocellular carcinoma (HCC) remains one of the leading causes of death worldwide. The complex etiology is attributed to many factors like heredity, cirrhosis, hepatitis infections or the dysregulation of the different molecular pathways. Nevertheless, the current treatment regimens have either severe side effects or tumors gradually acquire resistance upon prolonged use. Thus, developing a new selective treatment for HCC is the need of the hour. Many anticancer agents derived from plants have been evaluated for their cytotoxicity towards many human cancer cell lines. Strigolactones (SLs)-a newly discovered class of phytohormones, play a crucial role in the development of plant-root and shoot. Recently, many synthetic analogues of SLs have demonstrated pro-apoptotic effects on different cancer cell lines like prostate, breast, colon and lung. In this study, we tested synthetic SLs analogues on HCC cell line-HepG2 and evaluated their capability to induce cell proliferation inhibition and apoptosis. Primary WST-1 assays, followed by annexin-V/7AAD staining, demonstrated the anti-proliferative effects. The SLs analogues TIT3 and TIT7 were found to significantly reduce HepG2 cell viability in a dose- and time-dependent manner and induce apoptosis. Interestingly, though TIT3 and TIT7 strongly affected cancer cell proliferation, both compounds showed moderate anti-proliferative effect on normal cells. Further, migration of cancer cells was suppressed upon treatment with TIT3 and TIT7 in a wound healing assay. In summary, these findings suggest that two SLs analogues TIT3 and TIT7 exert selective inhibitory effects on cancer cells most likely through targeting microtubules. SLs analogues could be used in future as potential anti-cancer candidates in chemotherapy.
CitationHasan MN, Choudhry H, Razvi SS, Moselhy SS, Kumosani TA, et al. (2018) Synthetic Strigolactone Analogues Reveal Anti-Cancer Activities on Hepatocellular Carcinoma Cells. Bioorganic & Medicinal Chemistry Letters. Available: http://dx.doi.org/10.1016/j.bmcl.2018.02.016.
SponsorsThe authors appreciate the endeavours of DSR in supporting this project financially and technically. This study was funded by the Deanship of Scientific Research (DSR), at King Abdulaziz University, Jeddah, under grant no: HiCi-1-130- 36.
- Anti-Cancer Effects of Citalopram on Hepatocellular Carcinoma Cells Occur via Cytochrome C Release and the Activation of NF-kB.
- Authors: Ahmadian E, Eftekhari A, Babaei H, Nayebi AM, Eghbal MA
- Issue date: 2017 Nov 24
- The cytotoxic and mechanistic effects of aaptamine on hepatocellular carcinoma.
- Authors: Li QL, Zhang PP, Wang PQ, Yu HB, Sun F, Hu WZ, Wu WH, Zhang X, Chen F, Chu ZY, Zhang JP, Chen SS, Lin HW
- Issue date: 2015
- Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
- Authors: Omar HA, Zaher DM, Srinivasulu V, Hersi F, Tarazi H, Al-Tel TH
- Issue date: 2017 Oct 20
- The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415.
- Authors: Zhang W, Chen B, Zhang Y, Li K, Hao K, Jiang L, Wang Y, Mou X, Xu X, Wang Z
- Issue date: 2017 Jun 3
- The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
- Authors: Pivonello C, Negri M, De Martino MC, Napolitano M, de Angelis C, Provvisiero DP, Cuomo G, Auriemma RS, Simeoli C, Izzo F, Colao A, Hofland LJ, Pivonello R
- Issue date: 2016 Mar 1